Literature DB >> 18752521

Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with vitelliform macular dystrophy.

Giuseppe Querques, Maria C Angulo Bocco, Gisele Soubrane, Eric H Souied.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752521     DOI: 10.1111/j.1600-0420.2007.01132.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  5 in total

1.  Multimodal fundus imaging in Best vitelliform macular dystrophy.

Authors:  Daniela C Ferrara; Rogério A Costa; Stephen Tsang; Daniela Calucci; Rodrigo Jorge; K Bailey Freund
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-23       Impact factor: 3.117

2.  A novel compound heterozygous mutation in the BEST1 gene causes autosomal recessive Best vitelliform macular dystrophy.

Authors:  L Zhao; S Grob; R Corey; M Krupa; J Luo; H Du; C Lee; G Hughes; J Lee; J Quach; J Zhu; P X Shaw; I Kozak; K Zhang
Journal:  Eye (Lond)       Date:  2012-03-16       Impact factor: 3.775

3.  A novel variant of autosomal recessive best vitelliform macular dystrophy and management of early-onset complications.

Authors:  Abdulrahman Albuainain; Hatlan M Alhatlan; Wajeeha Alkhars
Journal:  Saudi J Ophthalmol       Date:  2022-02-18

4.  Clinical Features and Genetic Findings of Autosomal Recessive Bestrophinopathy.

Authors:  Hae Rang Kim; Jinu Han; Yong Joon Kim; Hyun Goo Kang; Suk Ho Byeon; Sung Soo Kim; Christopher Seungkyu Lee
Journal:  Genes (Basel)       Date:  2022-07-04       Impact factor: 4.141

5.  BEST1 sequence variants in Italian patients with vitelliform macular dystrophy.

Authors:  Andrea Sodi; Ilaria Passerini; Vittoria Murro; Roberto Caputo; Giacomo Maria Bacci; Mirela Bodoj; Francesca Torricelli; Ugo Menchini
Journal:  Mol Vis       Date:  2012-11-17       Impact factor: 2.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.